Zoledronic acid in myeloma: MRC Myeloma IX.
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu
S Vincent
SV
Rajkumar
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary; D004002:Clodronic Acid / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality* / Q000556:secondary; D000077268:Pamidronate; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D004002:Clodronic Acid; D000077211:Zoledronic Acid; D000077268:Pamidronate